Resumen

ECHEZURIA, Luis; RISQUEZ, Alejandro  y  CASTILLO DE FEBRES, Olga. Vacunas meningocócicas. Arch Venez Puer Ped [online]. 2011, vol.74, n.4, pp.169-172. ISSN 0004-0649.

Meningococcal disease is a rare but serious infection, up to 10% of persons who contract disease die, so it is very important to immunized for Meningococcal disease protection and prevention. There are two types of vaccine: Polysaccharides that even though induces protection ,is not immunogenic in children younger of 2 years, don’t induce herd immunity and produce hypo responsiveness to a booster dose. Conjugate vaccines can be monovalent serogroup: C which demonstrated 93% reduction of serogroups C disease in population with high vaccine coverage.Also there are two quadrivalent serogroups A;C;W135;Y vaccines one conjugate to D (difteric toxoid) and other to /CRM 139(mutant no toxic of dfsteric toxin. Studies showed their immunogenicity up to 55 years and boths are safes. Epidemiological study with A;C;W135,Y/D disproves any evidence of increased risk to SGB after its administration Recommended schedule is to immunized all adolescent, with a dose plus a booster. High risk people of invasive meningococcal disease (anatomic or functional asplenia,terminal complement or prperdin deficiencies,HIV) should rereceived, 2 doses, plus boosters every 5 years.

Palabras clave : Menigococcal disease; Polysacccharide meningococcal vaccine; Quadrivalent conjugate A;C;W135;Y/D and A;C;W135; Y/CRM139 meningococcal vaccine.